Astrazeneca Ab

Nps Allelix Corporation

Nps Pharmaceuticals, Inc.

Jalaj Arora

Abdelmalik Slassi

Louise G Edwards

Methvin Benjamin Isaac

Tao Xin

David Wensbo

Tomislav Stefanac

Ashok Tehim

Thomas M Stormann

Donald A McLeod

Annika Kers

Alexander Minidis

Anne O'Brien

Martin Johansson

Scott T Moe

Ian Egle

Daryl Lynn Smith

Dean Brown

Susan M Sheehan

Karin Staaf

Methvin Issac

Ulrika Yngve

Helena Gyback

Bradford Van Wagenen

Johan Malmberg

William Michne

Christoffer Osterwall

Mangus Waldman

Karin Oscarsson

John Malmberg

Per-Olov Bergstrom

Veronica Profir

Caroline Eriksson

Tau Xin

Alexander Mindis

Donald Mcleod

Thomas Stormann

Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: wherein Ar, Ar, A, X, Y, m, n and R, R, R, Rand Rare as described in the specification, processes for their preparation, pharmaceutical formulations comprising them and their use in therapy, particularly in the therapy of neurological and psychiatric disorders associated with glutamate dysfunction.

Piperazines and piperidines as Mglur5 potentiators

The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.

Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.

Compounds for the treatment of neurological, psychiatric or pain disorders

The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.

Compounds

The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

The present invention relates to new compounds of formula I, wherein P, Q, X, X, X, X, X, R, R, R, R, R, R, G, M, M, M, m and n, are defined as in formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

Use of N-alkylamino-heterocylic compounds for the treatment of migraine

The present invention is directed to compounds useful in the treatment of migraine which have the general formula (II).

N-alkylamino-indoles for the treatment of migraine

Disclosed herein are compounds selective for a 5-HT,receptor, the compounds having the general formula (I):

5-Bicycloindole compounds

Growing community of inventors

Cambridge, Canada

Jalaj Arora